By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Janssen-Cilag AG 

Sihlbruggstrasse 111

Baar    6340  Switzerland
Phone: 41-41-7673434 Fax: 41-41-7673400





Company News
National Institute for Clinical Excellence (NICE) Rejects Early Use Of Janssen-Cilag AG's Velcade For Multiple Myeloma 11/12/2013 7:35:59 AM
Janssen-Cilag AG Release: ZYTIGA® Approved in the EU for Use in the Treatment of Metastatic Castration-Resistant Prostate Cancer Before Chemotherapy 1/11/2013 10:00:52 AM
Janssen-Cilag AG Acquires CorImmun 6/28/2012 10:31:03 AM
Basilea Pharmaceutica (BSLN.SW) Announces Discontinuation of Sale of Ceftobiprole by Janssen-Cilag AG, a Johnson & Johnson (JNJ) Company, In Switzerland 9/9/2010 7:03:45 AM
Janssen-Cilag AG Submits Marketing Authorisation Application in Europe for Paliperidone Palmitate for the Treatment of Schizophrenia 12/4/2009 10:14:44 AM
Janssen-Cilag AG Announces CHMP Delays European Commission Decision Process to Approve ZEVTERATM 2/24/2009 7:58:43 AM
PPD, Inc. (PPDI) to Receive Milestone Payments for First Regulatory Approvals of Priligy(TM) (Dapoxetine) in Finland and Sweden for Treatment of Premature Ejaculation 2/10/2009 10:07:18 AM
Janssen-Cilag AG's Priligy(TM) (Dapoxetine) Receives First Regulatory Approvals for the Treatment of Premature Ejaculation (PE) in Finland and Sweden 2/10/2009 6:59:29 AM
Janssen-Cilag AG New Biologic STELARA(TM) Receives Approval in Europe for Treatment of Moderate to Severe Plaque Psoriasis 1/22/2009 10:42:20 AM
Janssen-Cilag AG's New Antibiotic Against Serious Infections - Receives First Approval in Europe 11/13/2008 7:26:08 AM